CG Oncology (CGON) News
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
79.47-2.43 (-2.97%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CGON news summary
We found 12 recent headlines mentioning CG Oncology (CGON): 6 in the past week and 10 in the past 30 days, most often from Nasdaq, Seeking Alpha, Investing.com. For price context, CGON is down 2.97% at $79.47. The most recent story, "CG Oncology, Inc. Announces Topline Data for Phase 3 PIVOT-006 Trial", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest CG Oncology headlines
- CG Oncology, Inc. Announces Topline Data for Phase 3 PIVOT-006 TrialCG Oncology, Inc. announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with…NasdaqCGON, HEI.A
- Noteworthy Monday Option Activity: CGON, SLS, TGTAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CG Oncology Inc (Symbol: CGON), where a total of 14,793 contracts have traded so far,…NasdaqCGON, SLS, TGT
- CG Oncology rises on phase 3 data for bladder cancer immunotherapySeeking Alpha
- CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break OutCG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The biotech stock broke out. The post CG Oncology Exceeds Even The 'Most Bullish…Investor's Business Daily
- Why is CG Oncology stock surging today?Investing.com
- PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)– Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001)GlobeNewswire
- Why is CG Oncology stock surging today?Investing.com
- CG Oncology GAAP EPS of -$0.64 beats by $0.20, revenue of $1.6M beats by $1.07MSeeking Alpha
- CG Oncology, Inc. Q3 Loss Increases(RTTNews) - CG Oncology, Inc. (CGON) reported Loss for its third quarter of -$56.89 millionNasdaqCGON, SUN
- CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business UpdatesDALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.GlobeNewswire
- Notable Monday Option Activity: GE, CGON, BEAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in GE Aerospace (Symbol: GE), where a total of 24,969 contracts have traded so far,…NasdaqGE, CGON, BE
- Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmNEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their…PR Newswire